•
Dec 31, 2024
Zoetis Q4 2024 Earnings Report
Key Takeaways
Zoetis reported strong Q4 2024 results with revenue growth of 5% YoY, driven by a 9% operational increase in companion animal products. Net income increased by 11%, and adjusted EPS grew by 13%. The livestock segment declined due to divestitures.
Zoetis
Zoetis
Zoetis Revenue by Segment
Zoetis Revenue by Geographic Location
Forward Guidance
Zoetis expects 6% to 8% organic revenue growth in 2025, with strong momentum in companion animal therapeutics and international markets.
Positive Outlook
- Projected organic revenue growth of 6% to 8%
- Companion animal portfolio remains a strong growth driver
- Expansion in international markets, especially Europe and Latin America
- Continued investment in monoclonal antibody therapies
- Improved operational efficiencies expected to enhance margins
Challenges Ahead
- Livestock segment facing challenges from divestitures
- Potential foreign exchange headwinds impacting revenue
- Competitive pressures in the parasiticides market
- R&D and SG&A expenses expected to increase
- Macroeconomic uncertainties could affect global demand